Holding All the Chips

Incyte: Two messages

Incyte Genomics Inc. says it has abandoned the array space to emphasize its information services business. But the company's concurrent claims of broad intellectual property protection over genes, proteins and antibodies, and its budding interest in downstream development, may be providing a less clear picture to customers and potential competitors.

INCY (Palo Alto, Calif.) last week said it will shut down its Cambridge, U.K., SNP discovery facilities, which it received in 1998 when it acquired Hexagen Inc., and its Fremont, Calif., microarray facilities, which it got in 1997 through the acquisition of Synteni Inc. INCY also reduced its headcount by 400 to 700 employees.